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 Abstract 
 Background: Congenital melanocytic nevi (CMNs) are melanocytic neoplasms that can trans-
form into melanoma. However, this development is impeded in the majority of cases and 
mostly affects patients with large or giant CMNs.  Methods: To elucidate mechanisms that 
keep CMNs from malignant transformation, CMN tissue biopsies were investigated for p-ERK 
and senescence markers by immunohistochemistry and for SOX10/CD271 (p75 NTR ) by immu-
nofluorescence. CMN cells were cultivated, and MTT assays were performed for evaluating 
cell viability. Mutation status for NRAS and BRAF was performed by real-time PCR.  Results: 
13 CMNs (from patients aged 0.5–11.8 years, mean: 2.7) showed immunoreactivity for SOX10/
CD271 (p75 NTR ) in 34.2%. p-ERK was immunoreactive in 80% (4/5); β-galactosidase was sig-
nificantly stronger expressed in CMNs compared to melanocytic nevi of patients over 70 years 
(p = 0.0085). The 5 CMN cultures were immunoreactive for SOX10/CD271 (p75 NTR ) in 36.7%. 
By silencing SOX10 by siRNA in 2 CMN cell cultures, cell viability decreased significantly. 
NRAS Q61K mutation was found in 91.7% (11/12) and BRAF V600E in 6.3% of all analyzable CMNs 
(1/16).  Conclusions: Oncogene-induced senescence might prevent malignant transformation 
through activation of the mitogen-activated protein kinase pathway. SOX10 is necessary for 
the viability of human CMN cell cultures and may be responsible for clinical changes during 
aging.  © 2014 S. Karger AG, Basel 
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 Introduction 
 Congenital melanocytic nevi (CMNs) are benign melanocytic tumors that exist at birth 
 [1] . Their occurrence is caused by postzygotic mutations that result in a disruption of the 
melanocytic migration from the neural crest to the skin during embryonic development  [2] ; 
the earlier this event takes place, the larger the CMNs will develop in size  [3] . 
 CMNs share features with melanomas as they grow in diameter and also form secondary 
proliferations  [4, 5] . The risk of developing melanomas rises with the size of the lesion  [6] and 
is 2–3% in large and giant CMNs  [7–9] . However, melanomas in patients with large or giant 
CMNs may develop outside the CMN in other structures  [6, 7, 10–16] .
 Mutations in the NRAS gene are found in 70–81% of large and giant CMNs and in 80% of 
satellite nevi  [17] , while only 0–15% of the CMNs show a V600E mutation in the BRAF gene 
 [18–20] . However, the role of the mitogen-activated protein kinase (MAPK) signaling cascade, 
which plays a crucial role in melanoma development  [21] , has not been extensively investi-
gated for the CMNs so far. For noncongenital melanocytic nevi, activation of the downstream 
effector ERK has been found in 30–50% of dysplastic nevi while it is activated in 85% of mela-
nomas  [22–25] . 
 Mechanisms that drive CMNs into malignancy are yet inconclusive. Shakhova et al.  [26] 
have recently revealed the essential role of the transcription factor SOX10 for the formation 
of melanoma and the expression of SOX10 in CMNs. In this work, they suggest SOX10 to be a 
major driver for the genesis of melanomas and CMNs. Using the  Tyr::Nras Q61K INK4a –/– mouse 
model, Shakhova et al. could show that melanoma was induced by the NRAS Q61K mutation in 
the melanocyte lineage. By silencing SOX10 in melanoma cells, cell proliferation and survival 
as well as tumor formation in vivo  was suppressed. These findings propose that SOX10, which 
is important for neural crest development, is also involved in the development of melanoma 
and CMNs in mice. The question arises whether SOX10 is also required for the development 
of CMNs and melanoma in humans.
 Therefore, to affirm the presence of neural crest markers in human CMNs of children and 
to explore possible mechanisms that might keep the CMNs from malignancy, we explored the 
expression of the neural crest stem cell marker SOX10/CD271 (p75 NTR ), p-ERK and senes-
cence markers in CMNs in comparison to other nevus types and melanoma.
 Materials and Methods 
 Fresh tissue material of CMNs of children was received from the Department of Plastic 
and Reconstructive Surgery, Pediatric Hospital, University of Zurich, Switzerland. None of the 
children showed signs of leptomeningeal involvement of the CMNs, and none of them had 
developed melanoma so far. The 3 CMNs from older patients derived from the Department of 
Dermatology, University Hospital of Zurich, Switzerland, one of them (from a patient aged 74 
years) with a melanoma developing within the lesion. All other nevi were excised for cosmetic 
reasons. Written informed consent from all patients and/or their parents, respectively, was 
obtained following the guidelines of the Ethics Committee (Specialized Cantonal Ethics 
Subcommittee for Specialties Zürich, No. 840) and the Declaration of Helsinki. All lesions 
were histologically confirmed. 
 For further immunohistochemical investigations, 8 nevi with a histopathological 
congenital pattern derived from 1 female and 5 male patients, 8 melanocytic nevi without a 
congenital pattern and 8 melanocytic nevi from patients over 70 years were further taken. 
Five tissue specimens of primary melanoma which arose within a melanocytic nevus and 5 
melanoma metastases were used for additional control.
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 The BRAF and NRAS mutation status was determined by mutation-specific real-time PCR 
as previously described  [27] .
 Immunohistochemistry and Immunofluorescence, Mutation Status 
 Tissue samples were ﬁxed in 4% formaldehyde overnight and embedded in paraffin. 
Paraffin-embedded blocks were sectioned at 6-μm thickness and deparaffinized in xylene, 
hydrated with ethanol and rinsed in distilled water. Forty-minute citrate buffer incubation 
(10 m M citric acid, 0.05% Tween 20, pH 6) in a steamer was used for epitope retrieval. After-
wards, sections were cooled for 20 min and rinsed in phosphate-buffered saline. The following 
primary antibodies were used during the 0.5-hour staining at room temperature: MelanA 
(Leica Microsystems, 1: 60), HMB45 (Dako, 2: 1), MITF (Dako, clone D5, 1: 60), p16 (B+D, 
1: 100), KI67 (Dako, 1: 3), β-galactosidase (ICN Pharmaceuticals; 1: 100) and p-ERK [Cell 
Signaling, Phospho-p44 / 42 (ERK1/2), 1: 200]. Chromogenic detection was performed using 
the alkaline phosphatase-antialkaline phosphatase method except for p-ERK for which the 
phosphatase-antialkaline phosphatase method was used. For p-ERK, mammary carcinoma 
served as controls; for CD271 (p75 NTR ) and SOX10 control, brain tissue was used. 
 Semiquantitative assessment was performed for stain intensity (0 = none; 3 = strong) 
and percentage of reactive cells (0–100%); the product of both was taken (grade × percentage).
 For immunofluorescent double-staining against SOX10/CD271 (p75 NTR ), slides were 
preincubated with bovine serum albumin 1% for 30 min and incubated with primary anti-
bodies [SOX10: R&D; CD271 (p75 NTR ): Alomone lab., each 1: 400] overnight at 4 ° C, followed 
by the incubation with Cy3-conjugated anti-mouse and Alexa488-conjugated anti-rabbit 
secondary antibodies for 1 h at room temperature (Jackson ImmunoResearch Laboratories, 
and Invitrogen, each 1: 500). Nuclei were counterstained with Hoechst 33342 solution (Invi-
trogen, 1: 10,000). Staining only with secondary antibodies was used to evaluate background 
fluorescence and unspecific binding. Analysis was performed semiquantitatively by visual 
examination with an Olympus BX51TF. SOX10/CD271 (p75 NTR ) double-reactivity was eval-
uated using an upright fluorescence microscope and upright confocal microscope (AF6000 
and SP2, Leica Microsystems) at ×40 magnifications. Photographs were taken using a spectral 
detection camera on the system. Positivity was assessed when cells were double-positive for 
nuclear SOX10 and plasma membrane CD271 (p75 NTR ) staining; histological co-localization 
of positive subpopulation was evaluated. Hair follicles within the tissue served as a positive 
control; for a negative control, Merkel cell carcinoma [Mangana J. et al., unpublished data] was 
taken. Imaging and analysis was performed using the integrated Leica Software.
 Cell Cultures 
 Fresh tissues of 4 large to giant CMNs of children and 1 of a 75-year-old patient served 
for the establishment of cell cultures. Cells were released from tissue sections, and cultured 
as adherent cells for 10–14 passages using melanocyte growth medium (Melanocyte Growth 
Medium M2, PromoCell). Another portion was cultured for nonadherent spheres in D-MEM/
F-12 (1: 1) medium [supplemented with B27 stem cell culture supplement without vitamin 
A, basic fibroblast growth factor 2, epidermal growth factor, penicillin, streptomycin, 
Fungizone, and human leukemia-inhibiting factor in hydrophobic poly-HEMA-coated flasks 
for up to 4 passages after culturing cells as adherent cells for 6–8 passages (all Invitrogen 
Corporation)]. 
 Immunocytological detection of MelanA, and SOX10/CD271 (p75 NTR ), was performed 
with cell pellets containing 105 cells, resuspended in 4% formalin, fixed for 6 h at 4  °  C, and 
mixed in 1.5% NuSieve low-melting agarose (FMC Biopractice). After cooling, suspension was 
injected into chambers and dehydrated in ethanol and xylene. Blocks of paraffin-embedded 
cells were sectioned at 6-μm-thick slides for staining as described above. For anti-β-
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galactosidase detection cytospins using 2 × 104 trypsinized and washed cells were made. 
Cells were centrifuged onto a SHANDON glass and fixed in acetone. Staining was performed 
as described above.
 MTT Assay and siRNA Knockdown 
 Cell viability was measured by the MTT assay for the two CMN cell cultures (ZM07 and 
SC06) as previously described  [28, 29] . Silencing RNA (siRNA) transfection of CMN cell 
cultures was carried out using INTERFERin transfection solution according to the manufac-
turer’s protocol (Polyplus-transfection, Illkirch, France). Cells were transfected with 10 n M of 
siRNA (Qiagen) for 72 h before RNA was extracted. As control siRNA, the All-Star negative 
siRNA sequence (Qiagen) was used, and gene-specific siRNAs targeting siSOX10 (SI00729414, 
SI00729421) were obtained from Qiagen.
 Statistics 
 Statistical analyses were conducted with GraphPad 5 (San Diego, Calif., USA) for Windows. 
A p value of less than 0.05 was considered as statistically significant. For evaluating the p 
values in the immunohistochemistry section, unpaired t test was used. Standard deviation 
(SD) and 95% confidence intervals (CI) were computed.
 Results 
 Demographics and Mutation Status 
 Thirteen CMNs (all present at birth) were derived from 5 girls and 5 boys with a median 
age of 1.2 years (0.5–11.8 years) and had a median maximal diameter of 7 cm (2–30 cm). 
Comprehensive patient demographics are illustrated in online supplementary table 1 (for all 
online suppl. material, see www.karger.com/doi/10.1159/000362490). 
 The NRAS Q61K mutation was found in 91.7% of all analyzable CMNs (11/12); in 4 cases, 
data were not available, most likely due to low DNA quality. The BRAF V600E mutation was 
found in 1 of 16 CMNs, and 15 CMNs were wild type for this mutation (online suppl. table 1). 
 Immunohistochemical and Immunofluorescence Analysis 
 p-ERK and MITF  
 The p-ERK expression in most CMNs was stronger in the upper dermis with weaker 
staining towards deeper structures (data not shown). Remarkably, CMNs that showed a deep 
infiltration demonstrated an inverse pattern with more immunoreactivity in deeper struc-
tures than in the upper parts of the dermis ( fig. 1 a, b). Hair follicles and blood vessels were 
strongly immunoreactive in both groups ( fig. 1 b). Interestingly, within each melanoma metas-
tasis, p-ERK was unequally expressed in different, sharply demarcated areas ( fig. 1 e).
 Four of 5 CMNs (80%) showed immunoreactivity to p-ERK while 100% of the primary 
melanoma and melanoma metastases were immunoreactive (each 5/5) ( fig. 1 c–g). The nevi 
around the primary melanoma showed a trend for less immunoreactivity to p-ERK than the 
primary melanoma within the same nevus although it was not significant (p = 0.0856). p-ERK 
immunoreactivity in melanoma metastasis was significantly stronger than in melanocytic 
nevi (p < 0.0001), CMN (p = 0.0052), primary melanoma (p = 0.0388) and the associated mela-
nocytic nevus (p = 0.0017) ( fig. 1 g).
 MITF expression did not differ within the various nevus groups (i.e. CMN, noncongenital 
melanocytic nevi with a congenital pattern, melanocytic nevi of patients over 70 years, other 
melanocytic nevi).
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 Senescence and Proliferation 
 CMNs of the children were significantly more immunoreactive to β-galactosidase than 
melanocytic nevi of patients over 70 years (p = 0.0085;  fig. 2 o). Except for the hair follicles, 
which strongly expressed β-galactosidase, β-galactosidase expression was predominantly 
found in the junctional areas rather than in the deeper dermis ( fig. 2 d, h). However, CMNs 
which showed a deep dermal infiltration also showed stronger immunoreactivity in the 
deeper dermal areas ( fig. 2 l). β-Galactosidase-positive areas were also strongly immunore-
active for p16 but not for the proliferation marker KI67. As expected, CMNs were significantly 
less immunoreactive to the proliferation marker KI67 compared to primary melanoma (p  ≤ 
0.018) or melanoma metastasis (p = 0.0081) (online suppl. fig. 1).
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 Fig. 1. Immunohistochemistry for p-ERK in CMNs ( a , ×10 magnification;  b , ×20 magnification), primary 
melanoma arising within a melanocytic nevus ( c , ×10 magnification;  d , ×20 magnification, black arrows for 
melanoma, white arrows for nevus), and melanoma metastasis ( e , ×10 magnification;  f , ×40 magnification). 
The strong immunoreactivity in the blood vessels and hair follicles is indicated by the black arrows. White 
arrows indicate areas of strong and slight immunoreactivity, respectively, in the melanoma metastasis.  g Im-
munoreactivity in inner hair cells by boxplots. Note the significant difference of expression between mela-
noma metastases and CMN, melanocytic nevus, nevus-associated primary melanoma and the nevus around 
the melanoma.  h Boxplots of MITF expression between the different nevus types. Notice the lack of difference 
between all nevus groups. MN = Melanocytic nevus; Me = melanoma; MN and Me = nevus around the mela-
noma; Meta = melanoma metastases; Cong = melanocytic nevus with a congenital pattern; MN >70 = mela-
nocytic nevus of patients over 70 years. 
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 Neural Crest Stem Cell Markers 
 Immunofluorescent double-staining for SOX10/CD271 (p75 NTR ) on 12 samples showed 
double-positivity in 34.2% of the cells of each CMN specimen (95% CI = 0–70; SD = 22.45) 
except for the older patient of 18.5 years in whom no double-positivity was observed. In the 
other CMNs, expression was stronger in the upper dermis and continuously fainter towards 
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 Fig. 2. SOX10/CD271 (p75 NTR ) double-staining and anti-β-galactosidase staining of a compound type CMN 
deriving from a 3.7-year-old ( a–d ) and 1.9-year-old ( e–h ) child, respectively, and a CMN with deep dermal 
infiltration derived from a 0.8-year-old child ( i–l ). SOX10/CD271 (p75 NTR ) double-positivity is found in a few 
cells in the epidermal layer and in nests of the upper dermis ( b ,  f ,  j ). Deeper dermis is free of double-positive 
SOX10/CD271 (p75 NTR ) expressing cells in compound types ( c ,  g ) but strongly positive in the deep dermal 
infiltrating CMN ( k ).  d ,  h ,  l Corresponding β-galactosidase staining.  m–o Boxplots for SOX10 ( m ), CD271 
(p75 NTR ) ( n ) and β-galactosidase ( o ). CMNs showed significantly stronger SOX10 expression than other nevi 
(p = 0.0027) ( m ) and less expression of CD271 (p75 NTR ) than melanoma metastases (p = 0.0042) ( n ). CD271 
(p75 NTR ) was significantly stronger in primary melanoma associated with a melanocytic nevus than the sur-
rounding nevus (p = 0.00028) ( n ). β-Galactosidase was significantly stronger expressed in congenital nevi 
compared to nevi of patients over 70 years of age (p = 0.085) ( o ). MN = Melanocytic nevus; Me = melanoma; 
MN and Me = nevus around the melanoma; Meta = melanoma metastases; Cong = melanocytic nevus with a 
congenital pattern; MN >70 = melanocytic nevus of patients over 70 years. Red = CD271 (p75 NTR ); green = 
SOX10; white arrows = double-positive cells. 
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the deeper structures ( fig. 2 a–l). Adnexal structures such as hair follicles and blood vessels 
strongly expressed SOX10 and CD271 (p75 NTR ) (online suppl. table 2;  fig. 2 a–l).
 Immunohistochemistry showed significantly stronger immunoreactivity of SOX10 in 
CMNs of children compared to noncongenital melanocytic nevi (p = 0.0061) and nevi of 
patients over 70 years (p = 0.0035). There was no significant difference of SOX10 expression 
between nevus-associated primary melanoma, the surrounding nevus or melanoma metas-
tasis ( fig. 2 m). 
 CD271 (p75 NTR ) expression in CMNs showed a trend for less immunoreactivity compared 
to primary melanoma (p = 0.1325) but significant stronger expression in melanoma metas-
tases (p = 0.0057). Immunoreactivity to CD271 (p75 NTR ) was significantly stronger in primary 
melanoma associated with a melanocytic nevus than the surrounding nevus (p = 0.00028) 
( fig. 2 n).
 Morphology and Characteristics of Cultured Cells (MTT Assay) 
 CMN cells in cultures showed a robust behavior in terms of the ability for cultivation for 
several passages. Two of the CMN cell cultures were fast proliferating (i.e. ZM07: 9 passages 
were run through; FE08: 18 passages), one intermediate (SC06: 12 passages) and one slowly 
(LJ08: 8 passages) but could be kept in culture. One cell culture derived from the CMN of the 
74-year-old patient in which a primary melanoma arose within (SW34, only CMN material 
was taken, 12 passages). Notably, in the tissue which served for cell cultivation of the latter 
CMN, melanoma was histologically and immunohistochemically excluded.
 Freezing and defreezing for reculturing did not harm the cells. Notably, nevus cells 
changed their morphology after culturing over several weeks. At early passages, the cells 
showed a large body with only short dendrites, whereas over time cells extended the length 
of their dendrites while their body maintained the same morphology or even became smaller 
( fig. 3 ). Due to a slower proliferation rate after several weeks, the cells did not cluster as 
much as at the beginning. The granules and the pigment within their bodies, however, 
remained at the same level. Overall, the CMN cells derived from children survived through 
9–18 passages, and the cells from the 74-years-old patient continued growing through 12 
passages.
 66.7% of the cultured CMN cells were immunoreactive for MelanA (95% CI = 30–90;
SD = 32.2) and 100% were reactive for HMB45 (SD = 0). The cells showed double-reactivity 
for SOX10/CD271 (p75 NTR ) in 36.7% (95% CI = 10–60; SD = 25.2) of the cells of the children’s 
CMNs but only in 10% of the cells of the 74-year-old patient. In children’s CMNs, the cells were 
immunoreactive to β-galactosidase in 43.3% (95% CI = 30–50; SD = 11.6), to p16 in 41.7% 
(95% CI = 30–50; SD = 10.4), and to KI67 in 31.0% (95% CI = 2–60; SD = 41) ( fig. 3 ). 
 By knocking down SOX10 with 2 independent siRNAs in 2 different CMN cultures (ZM07 
and CS06), significant downregulation of SOX10 expression was observed ( fig. 4 a, b). Signif-
icant loss of cell viability in both CMN cultures was further investigated by the MTT assay with 
one of the cultures exhibiting an almost 50% reduction in viability as a result of SOX10 
knockdown (ZM07;  fig. 4 c, d).
 Discussion 
 There is no clear understanding of how CMNs develop – which are benign melanocytic 
neoplasms that are derived from the neural crest – and which mechanisms keep them from 
malignant transformation. So far, activating mutations of the MAPK kinase pathway have 
been suggested to play a role  [17, 19] . Indeed, depending on the size, 2–3% of the large CMNs 
develop into melanomas  [7–9, 30] . 
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 In the MAPK pathway, ERK is downstream of activating NRAS and BRAF mutations, and 
ERK phosphorylation indicates pathway activation. Unlike Jorgensen et al.  [23] , who did not 
find p-ERK immunoreactivity in nevi, and according to Oba et al.  [31] , who found 33% of 
nevus cells to be immunoreactive, we detected immunoreactive cells in 80% of the melano-
cytic nevi (20/25) and 100% of the malignant melanocytic lesions (10/10). However, mela-
nocytic nevi were less immunoreactive to p-ERK than primary melanoma or melanoma 
metastases (p = 0.04). These findings suggest that the majority of melanocytic nevi also 
harbor activating mutations in the MAPK pathway, although significantly less than in 
melanoma metastases. Within each melanoma metastasis, p-ERK was heterogeneously 
expressed in different areas indicating diverse subpopulations that may reside within one 
single metastasis  [32] . Notably, most blood vessels expressed strong immunoreactivity to 
p-ERK. This observation is consistent with clinical findings that melanoma patients under 
MEK inhibitors suffer consistently from edematous skin changes  [33] . 
 Loss of senescence is suspected to facilitate cellular malignancy  [34] . Several studies 
investigated the existence of senescence in CMNs of children with controversial results most 
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 Fig. 3. Adherent CMN cell cultures in phase contrast microscopy ( a ,  d ,  g ) with corresponding anti-SOX10/
CD271 (p75 NTR ) ( b ,  e ,  h ) anti-MelanA ( c ,  f ,  i ) staining of 1- and 2-year-old children ( a–c and  d–f ), respec-
tively, and of the 75-year-old patient ( g–i ). About 30% of the cells show immunoreactivity to SOX10/CD271 
(p75 NTR ) double-stain in the first two cultures, while the third culture reveals reactivity in about 10% of the 
cells. Cells of the first two cultures are all positive for anti-MelanA staining; the third culture is negative in 
the majority.  j–l Cell cultures of different passages of the 1.6-year-old girl (ZM07): passage 5 ( j ), passage 7 
( k ) and passage 9 ( l ). Note the elongation of the dendrites while the size of the body stays constant, and clus-
tering of the cells decreases. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
/1
2/
20
17
 8
:5
7:
25
 A
M
43Dermatopathology 2014;1:35–46
 DOI: 10.1159/000362490 
 Barysch et al.: Coexpression of SOX10/CD271 (p75 NTR ) and β-Galactosidase in Large to 
Giant Congenital Melanocytic Nevi of Pediatric Patients 
www.karger.com/dpa
© 2014 S. Karger AG, Basel
likely due to inconsistent techniques  [35–37] . Oncogene-induced senescence in melanocytic 
nevi due to activated oncogenes such as BRAF has been suggested earlier  [20, 38] . However, 
CMNs usually do not harbor BRAF mutations, as previously described and also shown by our 
results in which only 1 of 16 CMNs was mutated in the BRAF locus. Nevertheless, NRAS Q61K 
mutations are prevalent in CMNS as also shown by our samples, with the known activating 
mutations in 91.7% of all analyzable CMNs (11/12, 4 were not definable)  [17, 19] .
 We found a significantly higher expression of the senescence marker β-galactosidase in 
CMNs than in melanocytic nevi of patients over 70 years of age. β-Galactosidase in CMNs was 
co-localized with p16 while the proliferation marker KI67 was absent in these areas. This 
strongly indicates the presence of senescence in these areas  [35, 39] . 
 The transcription factor SOX10 is expressed in neural crest stem cells. It is required for 
maintaining multipotency but also for maintenance of differentiated cells  [40] . Primary 
melanoma and melanoma metastases show double-positivity for the neural crest stem cell 
marker SOX10/CD271 (p75 NTR ) in sphere-growing cell cultures  [41] . A mouse model with the 
NRAS Q61K mutation under the control of a tyrosine promoter and with a deletion of the cell 
cycle control gene INK4a has largely pigmented from birth that histopathologically mimics 
features of CMNs. SOX10 haploinsufficiency abrogated the NRAS Q61K -induced hyperpigmen-
tation and also prevented melanoma formation  [26] . 
 In our study, we show that human CMN cells are able to be cultured over many passages 
with good growth ability, showing heterogeneous morphology. SOX10/CD271 (p75 NTR ) 
immunofluorescence analysis performed on cell cultures revealed double-reactivity in 36.7% 
of the CMN cells derived from 2 children below the age of 2 years and was stronger compared 
to the one of the 74-years-old patient. These findings suggest neural crest-like features with 
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 Fig. 4. The results of MTT assays in cell lines ZM07 ( a ,  c ) and SC06 ( b ,  d ) upon SOX10 knockdown. SOX10 
mRNA expression was knocked down by two independent siRNAs for CMN cell cultures ZM07 ( a ) and SC06 
( b ). Cell viability was significantly reduced in both CMN cultures with a much stronger effect seen in the cell 
culture ZM07 with 60% viability ( c ) compared to SC06 with 85% viability ( d ) ( * p < 0.05;  * * * p < 0.001). 
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stem cell-like properties in the CMNs of young patients. As observed in the tissues of the older 
patients with CMN, this property can be lost during aging. This may explain the clinical 
changes of CMNs with proliferation and growth during time  [42, 43] . Furthermore, by showing 
significant loss of cell viability by knocking down SOX10 in CMN cell cultures, we show that 
SOX10 is necessary for viability of CMNs as it has been shown for human melanoma cells and 
in the NRAS mouse model  [26] . 
 Interestingly, areas in the CMNs that were immunoreactive for the senescence markers 
were also immunoreactive for SOX10/CD271 and p-ERK, including adnexal structures. Most 
of these cases even showed activated NRAS Q61K mutations. These findings strongly suggest 
the existence of oncogene-induced senescence (by NRAS Q61K mutation) in the CMNs and 
might be an underlying feature that prevents CMNs from malignant transformation despite 
an activated MAPK pathway.
 A limitation of this study is the small sample numbers. Moreover, broader analysis on 
protein levels and investigation of the dedifferentiation ability of the cells would help validate 
our observations. However, despite these limitations, the presented work might have clinical 
implications in terms of treatment and prevention. We show that SOX10 plays a role in the 
maintenance of human CMNs, as in melanoma. Hence, by targeting SOX10, CMNs might be 
treated or even prevented. 
 In conclusion, through NRAS Q61K activation, oncogene-induced senescence might protect 
CMNs from malignant transformation, although the MAPK pathway is activated. Concomitant 
expression of CD271 (p75 NTR ) and SOX10 in human CMN tissue and cell cultures might 
account for the proliferation and survival of CMNs over time but without malignancy.
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